Two weeks ago during its quarterly report, Novo Nordisk pointed to positive results in four of 10 Phase IIIa trials with oral semaglutide. This morning, the company revealed that the drug hit the mark in the reduction of blood sugar levels and weight in adults with type 2 diabetes.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,